By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ) (EGTX.ST)

STO Currency in SEK
kr 5.08
-kr 0.12
-2.31%
Last Update: 29 Aug 2025, 15:29
kr 1.82B
Market Cap
-4.84
P/E Ratio (TTM)
Forward Dividend Yield
kr 3.03 - kr 7.67
52 Week Range

EGTX.ST Stock Price Chart

Explore Egetis Therapeutics AB (publ) interactive price chart. Choose custom timeframes to analyze EGTX.ST price movements and trends.

EGTX.ST Company Profile

Discover essential business fundamentals and corporate details for Egetis Therapeutics AB (publ) (EGTX.ST) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

7 Apr 2011

Employees

38.00

CEO

Nicklas Westerholm

Description

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

EGTX.ST Financial Timeline

Browse a chronological timeline of Egetis Therapeutics AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 28 Apr 2026

Upcoming earnings on 24 Feb 2026

Upcoming earnings on 7 Nov 2025

Earnings released on 21 Aug 2025

Revenue for the quarter reached kr 14.50M , missing expectations by -12.12%.

Earnings released on 1 May 2025

EPS came in at -kr 0.20 surpassing the estimated -kr 0.24 by +16.67%, while revenue for the quarter reached kr 12.70M , missing expectations by -29.44%.

Earnings released on 26 Feb 2025

EPS came in at -kr 0.30 falling short of the estimated -kr 0.26 by -15.38%, while revenue for the quarter reached kr 10.80M , missing expectations by -32.50%.

Earnings released on 8 Nov 2024

EPS came in at -kr 0.30 matching the estimated -kr 0.30, while revenue for the quarter reached kr 9.40M , missing expectations by -41.25%.

Earnings released on 22 Aug 2024

EPS came in at -kr 0.20 surpassing the estimated -kr 0.29 by +31.03%, while revenue for the quarter reached kr 13.90M , beating expectations by +17.10%.

Earnings released on 3 May 2024

EPS came in at -kr 0.30 surpassing the estimated -kr 0.31 by +3.23%, while revenue for the quarter reached kr 12.10M , beating expectations by +8.33%.

Earnings released on 22 Feb 2024

EPS came in at -kr 0.30 matching the estimated -kr 0.30, while revenue for the quarter reached kr 32.60M , beating expectations by +110.32%.

Earnings released on 8 Nov 2023

EPS came in at -kr 0.30 falling short of the estimated -kr 0.21 by -42.86%, while revenue for the quarter reached kr 12.20M , beating expectations by +74.29%.

Earnings released on 22 Aug 2023

EPS came in at -kr 0.30 falling short of the estimated -kr 0.26 by -15.38%, while revenue for the quarter reached kr 5.90M , missing expectations by -5.60%.

Earnings released on 26 Apr 2023

EPS came in at -kr 0.30 falling short of the estimated -kr 0.28 by -7.14%, while revenue for the quarter reached kr 6.80M , beating expectations by +8.80%.

Earnings released on 22 Feb 2023

EPS came in at -kr 0.40 falling short of the estimated -kr 0.21 by -90.48%, while revenue for the quarter reached kr 5.60M , missing expectations by -46.05%.

Earnings released on 8 Nov 2022

EPS came in at -kr 0.30 falling short of the estimated -kr 0.18 by -66.67%, while revenue for the quarter reached kr 5.10M , missing expectations by -50.87%.

Earnings released on 19 Aug 2022

EPS came in at -kr 0.20 surpassing the estimated -kr 0.21 by +4.76%, while revenue for the quarter reached kr 4.66M , missing expectations by -55.11%.

Stock split effective on 27 Apr 2022

Shares were split 1089 : 1000 , changing the number of shares outstanding and the price per share accordingly.

Earnings released on 26 Apr 2022

EPS came in at -kr 0.18 falling short of the estimated -kr 0.17 by -5.88%, while revenue for the quarter reached kr 7.10M , missing expectations by -28.98%.

Earnings released on 17 Feb 2022

EPS came in at -kr 0.18 falling short of the estimated -kr 0.17 by -5.88%, while revenue for the quarter reached kr 3.21M , missing expectations by -8.26%.

Earnings released on 4 Nov 2021

EPS came in at -kr 0.09 surpassing the estimated -kr 0.19 by +52.63%, while revenue for the quarter reached kr 6.21M .

Earnings released on 19 Aug 2021

EPS came in at -kr 0.18 falling short of the estimated -kr 0.17 by -5.88%, while revenue for the quarter reached kr 25.03M .

Earnings released on 22 Apr 2021

EPS came in at -kr 0.09 surpassing the estimated -kr 0.22 by +59.09%, while revenue for the quarter reached kr 3.79M .

Earnings released on 17 Feb 2021

EPS came in at -kr 0.64 , while revenue for the quarter reached kr 4.89M .

Earnings released on 11 Nov 2020

EPS came in at -kr 0.46 , while revenue for the quarter reached kr 2.57M .

EGTX.ST Stock Performance

Access detailed EGTX.ST performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run